|
|||||
|
|
PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: The ODYSSEY KIDS study |
|
| Affiliation: | 1. University of Colorado School of Medicine, Aurora, CO, USA;2. Yale Pediatric Endocrinology, New Haven, CT, USA;3. Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA;4. Sanofi, Montpellier, France;5. Sanofi, Chilly-Mazarin, France;6. Hôpital Pitié Salpêtrière, Paris, France;7. Institute of Cardiometabolism and Nutrition, Paris, France |
| Abstract: |  |
| Keywords: | PCSK9 inhibitor Alirocumab Pediatrics Cardiovascular Heterozygous familial hypercholesterolemia |
| 本文献已被 ScienceDirect 等数据库收录！ | |